Asset Details
Do you wish to reserve the book?
Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer
Do you wish to request the book?
Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer
2024
Overview
Hepatocellular cancer (HCC) remained a life-threatening carcinoma. Agents for HCC imaging and therapy were expected to possess different intratumoral retention time. To construct an agent with different intratumoral retention time when applied for tumor imaging or therapy remained great values. A lasialoglycoprotein receptor (ASGPR) targeted lactobionic acid derivative (LABO) was constructed for fluorescent imaging and photodynamic therapy of HCC.
18
F labeled LABO (
18
F-LABO) was developed for PET imaging of HCC. LABO and
18
F-LABO showed similar molecular structure. LABO exhibited characteristic of viscosity and concentration-induced intratumoral in-situ self-assembly to expand the intratumoral retention. LABO was non-fluorescent at free stage, but emitted NIR fluorescence and generated irradiation-induced ROS after self-assembly for fluorescent imaging and photodynamic therapy. ASGPR specificity of LABO and
18
F-LABO was confirmed using HepG2 cell. Biodistribution and fluorescent imaging confirmed the different tumor retention time of LABO and
18
F-LABO when used for photodynamic therapy and PET imaging. PET imaging and photodynamic therapy were performed on HepG2 tumor bearing mice, which revealed that
18
F-LABO/LABO could specifically accumulated in the HepG2 tumor for tumor location/inhibition. LABO/
18
F-LABO with excellent HCC specificity but different intratumoral behaviors showed great values for the PET/NIR imaging and photodynamic therapy for HCC.
Graphical Abstract
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Animals
/ ASGPR
/ Cancer
/ Carcinoma, Hepatocellular - diagnostic imaging
/ Carcinoma, Hepatocellular - drug therapy
/ Chemistry and Materials Science
/ Fluorine Radioisotopes - chemistry
/ Hepatoma
/ Humans
/ Liver Neoplasms - diagnostic imaging
/ Liver Neoplasms - drug therapy
/ Mice
/ Photosensitizing Agents - chemistry
/ Photosensitizing Agents - pharmacology
/ Photosensitizing Agents - therapeutic use
